相关实验视频

Updated: Sep 16, 2025

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

BRD4770通过抑制亡和铁亡来防止DOX诱导的心脏毒性

Jingrong Shao¹, Rui Xiao¹, Ting Wang¹

¹Department of Biopharmaceutics, Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Pharmacy, Tianjin Medical University, Tianjin, China.

Science advances

|July 11, 2025

概括

一种新的化合物BRD4770通过保护心脏细胞免受损伤,有效地预防多克索鲁比诱导的心脏毒性. 这种表观遗传干预有望通过减少心脏损伤而减少更安全的化疗,而不会影响抗癌效应.

科学领域:

心脏病学心脏病学
在瘤学瘤学.
表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.

背景情况:

多克索鲁比 (DOX) 是一种强效的抗癌药物,但其使用受到心脏毒性限制,导致心肌细胞铁和亡.
DOX诱导的心脏毒性 (DIC) 涉及表观遗传改变,但系统的表观遗传干预仍然未被探索.

研究的目的:

识别和评估用于针对DOX诱导心脏毒性 (DIC) 的表观遗传干预的小分子.
研究BRD4770对DOX诱导的心肌细胞死亡的保护机制.

主要方法:

对表观遗传学化合物库进行查,以确定潜在的治疗剂.
在体外评估BRD4770对DOX治疗心肌细胞的影响,包括活性氧物种 (ROS) 生产,脂质过氧化和谷氨水平.
机理学研究涉及组织素甲基化,Nrf2/ATF4/SLC7A11信号通路分析.
开发一种ROS响应的,针对心脏的纳米脂质体配方,用于BRD4770的输送.

主要成果:

BRD4770显著抑制了DOX诱导的心肌细胞铁和亡.
BRD4770降低了ROS的产生和脂质过氧化,同时保持了谷氨的稳态.
该化合物缓解了DIC,但没有影响DOX的抗瘤功效.
从机制上讲,BRD4770促进了Nrf2/ATF4-SLC7A11信号传递,并减少了H3K9甲基化.
一种新的纳米脂质体配方增强了BRD4770对DIC的保护作用.

结论:

BRD4770是一种有希望的小分子,可以通过表观遗传调节来缓解DOX诱导的心脏毒性.
通过纳米脂质体的向输送可能会提高BRD4770的治疗潜力,以预防化疗相关的心肌病变.

更多相关视频

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

The Intrinsic Apoptotic Pathway

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...